BioWorld - Wednesday, December 24, 2025

Articles Tagged with ''targets''

Antibodies attacking cancer cell
Newco news

Solu secures $31M to progress two-pronged small molecule approach

Aug. 2, 2023
By Caroline Richards
Precision medicine startup Solu Therapeutics has raised $31 million in an oversubscribed seed round to advance a therapeutic candidate based on technology that identifies cell surface, tumor-associated targets that antibodies alone fail to latch onto. The company was founded by venture capital firm Longwood Fund and has high hopes for its cytotoxicity targeting chimera platform. “[It] has the potential to unlock new tumor-associated antigens and develop molecules that deplete pathogenic immune cells and extend the half-life of small-molecule antagonists and agonists,” CEO and co-founder of Solu, David Donabedian, told BioWorld.
Read More
Photomicrograph reveals some of the ultrastructural details seen in a Giardia lamblia cyst
Infection

Gl20S as a novel therapeutic target for antigiardial drug development

July 25, 2023
Giardia lamblia is a protozoan pathogen that colonizes the gastrointestinal tract and results in giardiasis. Recently, researchers from the University of California San Diego aimed to identify potent proteasome inhibitors that selectively target G. lamblia, as potential antigiardiasis therapeutics with low toxicity.
Read More
3D illustration of heart cross section
Cardiovascular

PTPN22 inhibition alleviates osteogenic responses in calcific aortic valve disease

July 25, 2023
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) has been previously linked to several chronic inflammatory disorders and it has been established that PTPN22 regulates T-cell receptor signaling. Recent studies have also shown that PTPN22 plays a role in thrombosis, suggesting its potential use as target for cardiovascular diseases. In the current study, researchers from Southern Medical University and affiliated organizations aimed to assess the role of PTPN22 in the pathogenesis of calcific aortic valve disease (CAVD).
Read More
Coronal plane slices of the brain comparing normal to Alzheimer’s.
Neurology/Psychiatric

Long noncoding RNA MALAT1 shows potential as new target for Alzheimer’s disease

July 24, 2023
Researchers from the University of Texas and University of Tennessee set out to determine if the long noncoding RNA (lncRNA) MALAT1 (metastasis associated lung adenocarcinoma transcript 1), which is known to regulate a subset of genes involved in synaptic plasticity, cognitive function and memory, plays an important role in Alzheimer’s disease (AD) pathology.
Read More
Illustration of motor neuron connecting to muscle fiber
Neurology/Psychiatric

Loss of cyclin D3 function reduces DMD pathogenesis in mdx mouse model

June 29, 2023
Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder affecting roughly 1 in 3,500 males. DMD is due to mutations in the dystrophin gene, which encodes for an exceptionally large 427 kD protein. DMD is characterized by repeated degeneration and regeneration of muscle fibers, but ultimately replacement of muscle with fibrotic and adipose tissue. Despite advances in gene therapy and improvements in quality of life, most patients still die by 30 years of age due to cardiopulmonary failure.
Read More
Colorized scanning electron microscope image of an osteosarcoma cell.
Immuno-oncology

Characterization of osteosarcoma-detecting MAb leads to identification of ALPL-1 as a CAR T target for treating osteosarcoma

June 27, 2023
Osteosarcomas (OS) are the most common malignant bone tumor. The disease originates within the fastest growing areas of the long bones of children and young adults, where the histologic hallmark of OS is malignant bone formation (osteoid). Improvements in treatments have proven difficult to date with metastatic OS remaining a bleak prognosis routinely leading to lung metastases to ultimately cause death.
Read More
Heme in red blood cells
Hematologic

NLRP12 senses heme plus PAMPs to trigger PANoptosis, aggravate hemolytic disease

June 21, 2023
Identification of the mechanisms of innate immune sensors is fundamental to the understanding of health and disease. The pattern recognition receptor (PRR) subfamily of nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) work by recognizing either pathogen-associated molecular patterns (PAMPs), endogenous damage-associated molecular patterns (DAMPs) or associated molecular...
Read More
Nephrology

HDAC9 inhibitors may be an effective therapeutic approach for chronic kidney disease

June 20, 2023
Chronic kidney disease (CKD) is the 10th leading cause of death in the United States because of the increased risk for cardiovascular mortality. The major functional cell type of the kidney, tubular epithelial cells (TECs), possess a limited ability to regenerate tissues. Infections can cause proximal G2/M cell cycle arrest, senescence and paracrine secretion of the profibrotic cytokines transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF), which stimulate extracellular matrix production ultimately leading to loss of the epithelial phenotype in TECs. Identification of targets controlling the G2/M cell cycle arrest in TECs may enable the development of therapeutics that can prevent CKD progression.
Read More